CA9 and renal cell carcinoma: Further exploration in this area includes a Phase I trial (ClinicalTrials.gov Identifier: NCT04969354) enrolling 20 patients with metastatic RCC refractory to prior therapies to assess CAIX-targeted CAR T cells.